These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cardiovascular effects of three calcium entry blockers in conscious dogs. Eigenmann R; Gerold M Arzneimittelforschung; 1987 Sep; 37(9):1020-5. PubMed ID: 3435596 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel antihypertensive agent, LY127210, in anesthetized and conscious spontaneously hypertensive rats. Ruffolo RR; Kurz K; Paget CJ J Pharmacol Exp Ther; 1985 Jan; 232(1):134-8. PubMed ID: 3838104 [TBL] [Abstract][Full Text] [Related]
6. Whole body and regional hemodynamic effects of minoxidil in the conscious dog. Humphrey SJ; Zins GR J Cardiovasc Pharmacol; 1984; 6(6):979-88. PubMed ID: 6084789 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological studies of N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899), a new long-acting antihypertensive vasodilator. Baldoli E; Bianchi G; Corsico N; Di Francesco GF Arzneimittelforschung; 1985; 35(5):818-26. PubMed ID: 2862874 [TBL] [Abstract][Full Text] [Related]
8. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent. Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of a new antihypertensive agent in several species. Salvati P; Caravaggi AM; Lamberti E; Monteggia M; Bianchi G Arzneimittelforschung; 1983; 33(8):1098-106. PubMed ID: 6685486 [TBL] [Abstract][Full Text] [Related]
10. Antihypertensive and hemodynamic actions of SCH 19927, the R,R-isomer and labetalol. Baum T; Watkins RW; Sybertz EJ; Vemulapalli S; Pula KK; Eynon E; Nelson S; Vliet GV; Glennon J; Moran RM J Pharmacol Exp Ther; 1981 Aug; 218(2):444-52. PubMed ID: 7252843 [TBL] [Abstract][Full Text] [Related]
11. The pharmacological effects of an unusual hypotensive agent: (SK & F 11197, 2,6-diamino-4-dimethylamino-ethoxy pyrimidine). I. Effects on the cardiovascular system. Ehrreich SJ; Heringslake JE; Warren FR; Weinstock J; Tedeschi RE Arch Int Pharmacodyn Ther; 1969 Jun; 179(2):284-302. PubMed ID: 5367304 [No Abstract] [Full Text] [Related]
12. Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system. Shen YT; Pittman TJ; Buie PS; Bolduc DL; Kane SA; Koblan KS; Gould RJ; Lynch JJ J Pharmacol Exp Ther; 2001 Aug; 298(2):551-8. PubMed ID: 11454916 [TBL] [Abstract][Full Text] [Related]
13. Analysis of the hypotensive action of prazosin. Constantine JW; McShane WK; Scriabine A; Hess HJ Postgrad Med; 1975 Nov; Spec No():18-35. PubMed ID: 1197141 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs. Hayashi N; Yamamoto S; Kometani M; Nakao K Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775 [TBL] [Abstract][Full Text] [Related]
15. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950. Anderson IK; Drew GM Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties. Uchida Y; Kawada M; Sawanobori K; Sonoki H; Inoue K; Mizuno K; Itou T; Tabunoki Y; Tsukamoto M; Ohashi Y; Kyotani Y; Shimizu N; Fujii M; Nakamura M Arzneimittelforschung; 1998 Mar; 48(3):219-31. PubMed ID: 9553677 [TBL] [Abstract][Full Text] [Related]
17. Systemic and regional hemodynamic effects of E614 (tripamide) as studied in conscious SHR. Nakai M; Matsui Y; Yamamoto J Arch Int Pharmacodyn Ther; 1986 Feb; 279(2):291-303. PubMed ID: 3963940 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs. Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs. Ueda M; Matsumura S; Masui M; Matsuura E; Kawakami M; Fujitomo H; Umeda T; Kagawa H; Hirohata S; Shima K Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815 [TBL] [Abstract][Full Text] [Related]
20. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats. Shin HS; Seo HW; Oh JH; Lee BH Arzneimittelforschung; 1998 Oct; 48(10):969-78. PubMed ID: 9825113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]